Stay updated on DONIMI Clinical Trial: Neoadjuvant Domatinostat, Nivolumab, Ipilimumab
Sign up to get notified when there's something new on the DONIMI Clinical Trial: Neoadjuvant Domatinostat, Nivolumab, Ipilimumab page.

Latest updates to the DONIMI Clinical Trial: Neoadjuvant Domatinostat, Nivolumab, Ipilimumab page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision: v3.4.2 was added and the prior government funding/operating status notice (v3.4.1) was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.8%

- Check21 days agoChange DetectedAdded a government funding notice and updated the history to v3.4.1, while removing v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.9%

- Check28 days agoChange DetectedNew UI elements include a glossary toggle, color-coded green additions and red deletions, and an updated revision label to enhance the history display. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference1%

- Check42 days agoChange DetectedThe Record History page now shows Revision: v3.3.4 replacing v3.3.3. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check64 days agoChange DetectedThe page shows a new revision label 'Revision: v3.3.3' and removes the 'HHS Vulnerability Disclosure' item along with the older 'Revision: v3.3.2' note; these are cosmetic changes that do not impact the trial information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check85 days agoChange DetectedRevision v3.3.2 was added to the history and revision v3.3.1 was removed; no study data or primary page content appears to be affected.SummaryDifference0.1%

Stay in the know with updates to DONIMI Clinical Trial: Neoadjuvant Domatinostat, Nivolumab, Ipilimumab
Enter your email address, and we'll notify you when there's something new on the DONIMI Clinical Trial: Neoadjuvant Domatinostat, Nivolumab, Ipilimumab page.